Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candidate into ...

Investing.com - TD Cowen initiated coverage on MBX Biosciences Inc (NASDAQ:MBX) with a Buy rating on Tuesday. The biotech company, currently valued at approximately $922 million, has seen its shares ...

Regular visitors to TopGear.com will know that Skoda has recently been digging into its back catalogue to reimagine classics using its current ‘Modern Solid’ design language – see the 110 R – and the ...

MBX Biosciences took advantage of the renewed bid for weight loss drug developers by taking two full days to market a follow-on stock sale, giving investors time to absorb a spike in its shares in ...

MBX Biosciences (NASDAQ:MBX) has priced its public offering of 11,108,055 shares at $18.00 per share. The upsized offering is expected to generate gross proceeds of approximately $199.9 million for ...

Shares of MBX Biosciences jumped after the company said it would release topline results from a Phase 2 study of its hypoparathyroidism treatment on Monday. The stock was up 33% at $13.30 in premarket ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. MBX Biosciences, Inc. ( (MBX)) has shared ...

Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in Q3 2025 MBX 4291 Phase 1 trial initiation in obesity anticipated in Q3 2025 $224.9 million ...